Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Curr Med Chem ; 17(28): 3253-61, 2010.
Article in English | MEDLINE | ID: mdl-20666719

ABSTRACT

BACKGROUND: Hyperhomocysteinemia has been associated with cognitive dysfunction and dementia. The incidence of dementia in Parkinson's Disease (PD) patients is higher than in the general population and plasma Homocysteine concentrations are increased in L-dopa treated PD patients. OBJECTIVE: We evaluated the possible correlations between L-Dopa related hyperhomocysteinemia and cognitive dysfunction in PD. METHODS: A Medline literature search was performed to identify all published studies on Homocysteine and cognitive dysfunction and dementia during the course of PD from 1966 to 31/03/2010. RESULTS: Sixteen studies were found for review; ten studies focused on homocysteine and cognitive dysfunction in PD patients, five on homocysteine and PD dementia and two on homocysteine and markers of neurodegeneration in PD. The design of the study was retrospective in 14 studies, while 2 had a prospective design, with a variable follow-up period (from 24-weeks to 2 years). In most of the studies plasma homocysteine levels significantly correlated with cognitive functions, dementia and markers of neurodegeneration in PD patients. However, some studies did not confirm these findings. Several factors may concur to explain these partially conflicting results, including the retrospective design of the studies, their small sample size, their high percentage of excluded patients, and the use of a wide range of neuropsychological tasks in assessment of cognitive dysfunctions across the available studies. CONCLUSIONS: Available data seem to indicate a potential role of L-dopa related hyperhomocysteinemia on cognitive impairment and dementia during the course of PD.


Subject(s)
Antiparkinson Agents/adverse effects , Cognition Disorders/etiology , Dementia/etiology , Hyperhomocysteinemia/etiology , Levodopa/adverse effects , Parkinson Disease/complications , Antiparkinson Agents/therapeutic use , Homocysteine/metabolism , Humans , Levodopa/therapeutic use , Neurons/metabolism , Parkinson Disease/drug therapy , Parkinson Disease/pathology
2.
Cerebrovasc Dis ; 22(4): 286-93, 2006.
Article in English | MEDLINE | ID: mdl-16847397

ABSTRACT

BACKGROUND: Intracranial haemorrhage (ICH) is the type of stroke associated with the highest death rate, and about 30% of ICH occurs in patients on antithrombotic treatment. This study relates clinical presentations and outcome of ICH patients on oral anticoagulant (OA) or antiplatelet (AP) therapy admitted to 33 Italian emergency departments (ED). METHODS: Consecutive patients were enrolled after cranial computed tomography (CT). Primary outcome was the Modified Rankin Scale (MRS) score at 3 months of follow-up. Common descriptive statistics were computed after stratification for traumatic or spontaneous ICH and identification of the anatomical location of bleeding. Multivariate logistic regression was used to assess predictors of death. RESULTS: We recruited 434 patients on AP therapy and 232 on OA. There were 432 spontaneous and 234 traumatic ICH patients. The proportions of AP and OA patients undergoing neurosurgery were 21.8 and 19.4%, respectively, while < 30% underwent procoagulant medical treatment. At the 3-month follow-up, the case fatality rate was 42.0%, while disability or death (MRS 3-6) was 68.1%. The odds ratio for death in OA versus AP patients was 2.63 (95% CI 1.73-4.00) in the whole population and 2.80 (95% CI 1.77-4.41) in intraparenchymal event patients. Glasgow Coma Scale, age, spontaneous event and anticoagulant use were found to be predictors of death both in traumatic and spontaneous events. CONCLUSION: This study confirms the high prevalence of death or disability in OA and AP patients with ICH. As far as the determinants of mortality and disability are concerned, the results of this study might be useful in the clinical management and allocation of resources in the ED setting. The observed low use of procoagulant therapy highlights the need for ED educational programmes to heighten the awareness of available and effective haemostatic treatments.


Subject(s)
Anticoagulants/therapeutic use , Coagulants/therapeutic use , Emergency Service, Hospital , Fibrinolytic Agents/therapeutic use , Intracranial Hemorrhages/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Stroke/drug therapy , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Female , Humans , Intracranial Hemorrhages/mortality , Intracranial Hemorrhages/rehabilitation , Italy , Male , Middle Aged , Prospective Studies , Recovery of Function , Stroke/mortality , Stroke Rehabilitation , Survival Analysis , Thromboembolism/drug therapy
3.
J Neurol Neurosurg Psychiatry ; 77(2): 252-4, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16421132

ABSTRACT

BACKGROUND: Previous family studies provided evidence that blepharospasm (BSP) can aggregate in families but did not give accurate and reliable information on the characteristics and degree of familial clustering. AIM: To evaluate the proportion of familial and non-familial BSP cases, the clinical expression of dystonia within families, the inheritance pattern, and the extent of penetrance. METHODS: The study was based on the examination of the first degree relatives of 56 probands with primary BSP. RESULTS: The 56 families produced a potential population of 436 first degree relatives of whom 296 were alive and 233 were examined. The proportion of index patients with at least one first degree relative affected by BSP, or adult onset dystonia other than BSP, was 27%. There was a remarkable degree of phenotypic variability of dystonia within families. Similar segregation ratios were calculated for probands' siblings and children. Under the assumption of autosomal dominant transmission of adult onset dystonia, penetrance was about 20%. CONCLUSIONS: The findings of this family study are relevant for accurately counselling the families of patients with BSP and may help identify the most appropriate study design to explore genetic susceptibility in BSP.


Subject(s)
Blepharospasm/genetics , Disease Susceptibility/congenital , Adolescent , Adult , Aged , Aged, 80 and over , Child , Chromosome Aberrations , Cluster Analysis , Dystonia/genetics , Family , Female , Gene Frequency/genetics , Genes, Dominant , Genetic Testing , Genotype , Humans , Male , Middle Aged , Phenotype
4.
Eur J Neurol ; 12(5): 365-8, 2005 May.
Article in English | MEDLINE | ID: mdl-15804266

ABSTRACT

Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment and dementia. L-dopa treatment may represent an acquired cause of hyperhomocysteinemia (HHcy), as evidenced by studies in rats as well as in Parkinson's disease (PD) patients. Folate and cobalamin status also seems to influence the effects of L-dopa on plasma Hcy levels; therefore B-vitamins supplementation has been proposed to reduce the HHcy in L-dopa treated PD patients. Plasma Hcy, folate, and cobalamin levels were evaluated in 20 PD patients treated with L-dopa in the baseline condition and following a 5-week period of treatment with cobalamin and folate; results were compared with 35 controls. Analysis of data revealed that Hcy levels were higher in L-dopa treated PD patients when compared with age- and sex-matched controls and that supplementation of the diet with cobalamin and folate is effective in reducing Hcy concentrations; these findings may have important implications in the treatment of PD patients who are potentially at risk for vascular diseases and cognitive impairment or dementia.


Subject(s)
Antiparkinson Agents/adverse effects , Folic Acid/therapeutic use , Hyperhomocysteinemia/prevention & control , Levodopa/adverse effects , Vitamin B 12/therapeutic use , Aged , Female , Folic Acid/blood , Homocysteine/blood , Humans , Hyperhomocysteinemia/blood , Hyperhomocysteinemia/etiology , Male , Middle Aged , Parkinson Disease/blood , Parkinson Disease/drug therapy , Vitamin B 12/blood
5.
Parkinsonism Relat Disord ; 11(2): 131-3, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15734674

ABSTRACT

Elevated plasma homocysteine (Hcy) concentrations have been reported in L-dopa treated Parkinson's disease (PD) patients, suggesting that L-dopa treatment is an acquired cause of hyperhomocysteinemia. Aim of this study is to evaluate the effects of different antiparkinsonian drugs on Hcy concentrations. We compared Hcy, B(12) and folate levels in 45 PD patients (15 treated with dopamine-agonists, 15 with L-dopa and 15 with L-dopa plus a catechol-O-methyltransferase-inhibitor (COMT-I) and in 15 controls. Analysis of data revealed that L-dopa administration significantly increases Hcy concentrations and that the addition of COMT-I effectively reduces the homocysteinemia.


Subject(s)
Antiparkinson Agents/administration & dosage , Homocysteine/blood , Levodopa/administration & dosage , Parkinson Disease/blood , Parkinson Disease/drug therapy , Aged , Catechol O-Methyltransferase Inhibitors , Dopamine Agonists/administration & dosage , Enzyme Inhibitors/administration & dosage , Female , Folic Acid/blood , Humans , Male , Middle Aged , Vitamin B 12/blood
6.
Neurol Sci ; 24(3): 176-7, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14598074

ABSTRACT

Progressive supranuclear palsy (PSP or Steele-Richardson-Olszewski syndrome) is one of the most-common types of atypical parkinsonism. To characterize the natural history and the clinical features of PSP, we reviewed the records of 25 patients followed in our clinic since 1991, with a clinical diagnosis of PSP according to NINDS and Golbe criteria. Progressive onset of early bilateral bradykinesia and postural instability with falls during the 5th decade strongly support the diagnosis of PSP in our patients. Pseudobulbar symptoms are very common at onset and during the course of the illness.


Subject(s)
Hypokinesia/etiology , Movement Disorders/etiology , Parkinsonian Disorders/etiology , Supranuclear Palsy, Progressive/physiopathology , Age of Onset , Aged , Cognition Disorders/etiology , Deglutition Disorders/etiology , Dysarthria/etiology , Female , Follow-Up Studies , Humans , Male , Retrospective Studies , Supranuclear Palsy, Progressive/complications , Supranuclear Palsy, Progressive/diagnosis
7.
Neurol Sci ; 23 Suppl 2: S123-4, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12548374

ABSTRACT

According to El Escorial criteria, amyotrophic lateral sclerosis (ALS), combined with other neurologic disorders, such as dementia and parkinsonism, is defined as ALS-plus. These overlaping syndromes are extremely rare. Here we report 5 cases (3 men, 2 women) of ALS-plus; mean age at the onset of symptoms was 67 years (range, 65-72). In 3 patients, motoneuronal signs preceded the onset of parkinsonian syndrome. In 4 cases, the clinical picture was characterized by the prevalence of motoneuronal signs. Parkinsonism was poorly responsive to L-dopa treatment in all patients. The clinical course did not differ from that expected in patients with only ALS. Our clinical observations and neuropathological reports of nigral neuronal loss in ALS patients suggest a common pathogenic mechanism underlying these disorders.


Subject(s)
Amyotrophic Lateral Sclerosis/complications , Dementia/complications , Parkinsonian Disorders/complications , Aged , Amyotrophic Lateral Sclerosis/physiopathology , Antiparkinson Agents/therapeutic use , Dementia/physiopathology , Female , Humans , Levodopa/therapeutic use , Male , Parkinsonian Disorders/physiopathology
8.
Neurol Sci ; 22(1): 109-10, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11487183

ABSTRACT

A clinical retrospective study was carried out in a population of 366 Parkinson's disease (PD) outpatients, to analyse the efficacy and tolerability of nonergoline and ergoline dopamine agonist (DA), in monotherapy or in combination with L-dopa. Safety was comparable in both groups except for higher occurrence of gastrointestinal symptoms in ergoline group and somnolence in nonergoline group. No significant difference concerning efficacy and tolerability was found during DA monotherapy. Mean age at PD onset was slightly higher in patients withdrawing DA monotherapy for adverse events comparing to patients who needed the addition of L-dopa (60.36 +/- 7.53 versus 54.88 +/- 10.75; p<0.05), suggesting that older age at the onset of the disease increases the risk for adverse events during DA monotherapy. The follow-up of the remaining patients still in monotherapy with DA will allow a better evaluation of these aspects.


Subject(s)
Aging/drug effects , Dopamine Agonists/adverse effects , Drug Tolerance/physiology , Parkinson Disease/drug therapy , Age of Onset , Aged , Aging/physiology , Benzothiazoles , Bromocriptine/administration & dosage , Bromocriptine/adverse effects , Dopamine Agonists/administration & dosage , Drug Administration Schedule , Drug Interactions/physiology , Drug Therapy, Combination , Ergolines/administration & dosage , Ergolines/adverse effects , Ergolines/agonists , Female , Follow-Up Studies , Humans , Indoles/administration & dosage , Indoles/adverse effects , Levodopa/administration & dosage , Levodopa/adverse effects , Lisuride/administration & dosage , Lisuride/adverse effects , Male , Middle Aged , Pergolide/administration & dosage , Pergolide/adverse effects , Pramipexole , Retrospective Studies , Thiazoles/administration & dosage , Thiazoles/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...